Monitoring platelet GP IIb/IIIa antagonist therapy.
Coller
B S
BS
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003328:Coronary Thrombosis / Q000517:prevention & control*; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D007206:Individuality; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D010979:Platelet Function Tests / Q000379:methods*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000032:analysis / Q000037:antagonists & inhibitors*; D013915:Thrombasthenia / Q000097:blood
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab